Nawrotowa postać szpiczaka plazmocytowego leczona długotrwale lenalidomidem w monoterapii – opis przypadku

Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic system. Introduction to therapy over a decade ago new therapeutic strategies, including immunomodulatory drugs (IMiDs) significantly improved the prognosis in this type of cancer. Despite high response rate multiple myeloma is characterized by a relapsing course in most patients and becomes more resistance to treatment. The article presents the case of a 49-year-old patient with relapsed multiple myeloma treated with lenalidomide monotherapy for 36 months.